CHMP recommends Kineret for CAPS treatment
Swedish Orphan Biovitrum AB (Sobi) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Kineret (anakinra) for the treatment of patients with Cryopyrin-Associated Periodic Syndromes (CAPS). The opinion is based on a positive benefit risk assessment of the results from a long-term treatment study in children and adults with NOMID/CINCA, the most severe form of CAPS.
In December 2012, Kineret became the first and only FDA-approved therapy for NOMID/CINCA. Sobi will provide Kineret for home treatment in a prefilled syringe with a graduated label to allow flexible dosing in children.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins